Alexion bets $1.4B on Portola and its laggard bleeding drug Andexxa

Alexion
Back in December, Alexion shot down an activist investor's request to put itself on the block. (Alexion)

Alexion has made no secret of its plan to diversify beyond its blockbuster rare disease franchise. Now, the company has taken a flier out on a disappointing drug that targets severe bleeding—and it's hoping to parlay its hospital contacts into a sales boost that'll appease unruly investors.

Alexion agreed to buy Portola Pharmaceuticals and its sole approved medicine, anticoagulant reversal agent Andexxa, in a deal valued at around $1.4 billion, the drugmakers said Monday. 

That's $18 per share in cash—a 131% premium on Portola's Monday closing price of $7.76 per share. 

The Portola buyout will take Alexion beyond a rare-disease portfolio dominated by blockbuster C5-inhibitor Soliris and follow-up drug Ultomiris. The centerpiece of the deal is a bleeding reversal agent, Andexxa, designed for patients using two common anticoagulant drugs, Xarelto and Eliquis.

So far, Andexxa has delivered disappointing sales, but Alexion still sees promise—even if it'll take a while for that promise to pay off.

Execs were straightforward with analysts on a Monday call, saying the Portola buy would take time to add value given Andexxa's minuscule commercial penetration––around 3% in the factor Xa reversal agent market––and a raft of strategic changes yet to be rolled out. 

"The way we look at value here is long-term value," CFO Aradhana Sarin told analysts. "This is a diversification play for us .. [and] we'll need to have a really heavy lift in the next few quarters and years to drive value here."

However, Alexion believes its commercial team can lean on a "near-complete overlap" between the healthcare providers its current sales and outreach teams now target and the potential market access points for Andexxa, CCO Brian Goff said. The Portola drug is used in emergencies in acute-care settings, and Soliris and Ultomiris are often first used in hospitalized patients.

Andexxa currently sports the FDA's approval to reverse the effects of severe bleeding in patients taking Johnson & Johnson and Bayer's Xarelto, or Bristol Myers Squibb and Pfizer's Eliquis. The drug's patents currently protect its market exclusivity through 2030, Alexion said.

In all, Alexion predicts that Andexxa could expand far beyond the 17.7 million patients treated in 2020, with an immediate market boost in the U.S. and future rollouts in the EU and elsewhere, Goff said.

RELATED: Alexion shoots down 'proactive' sale demand from activist investor

Suggested Articles

Bayer has withdrawn part of a proposed Roundup settlement after a judge questioned how it's handling potential future claims.

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

The CEOs for COVID-19 vaccine partners Pfizer and BioNTech are sounding confident in their program as they gear up for phase 3.